Works matching IS 20457634 AND DT 2014 AND VI 3 AND IP 6


Results: 21
    1
    2

    Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries.

    Published in:
    Cancer Medicine, 2014, v. 3, n. 6, p. 1517, doi. 10.1002/cam4.302
    By:
    • Porta, Camillo;
    • Levy, Antonin;
    • Hawkins, Robert;
    • Castellano, Daniel;
    • Bellmunt, Joaquim;
    • Nathan, Paul;
    • McDermott, Ray;
    • Wagstaff, John;
    • Donnellan, Paul;
    • McCaffrey, John;
    • Vekeman, Francis;
    • Neary, Maureen P.;
    • Diaz, Jose;
    • Mehmud, Faisal;
    • Duh, Mei Sheng
    Publication type:
    Article
    3
    4
    5
    6

    Issue Information.

    Published in:
    Cancer Medicine, 2014, v. 3, n. 6, p. i, doi. 10.1002/cam4.123
    Publication type:
    Article
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17

    Poly ( ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.

    Published in:
    Cancer Medicine, 2014, v. 3, n. 6, p. 1579, doi. 10.1002/cam4.317
    By:
    • Owonikoko, Taofeek K.;
    • Zhang, Guojing;
    • Deng, Xingming;
    • Rossi, Michael R.;
    • Switchenko, Jeffrey M.;
    • Doho, Gregory H.;
    • Chen, Zhengjia;
    • Kim, Sungjin;
    • Strychor, Sandy;
    • Christner, Susan M.;
    • Beumer, Jan;
    • Li, Chunyang;
    • Yue, Ping;
    • Chen, Alice;
    • Sica, Gabriel L.;
    • Ramalingam, Suresh S.;
    • Kowalski, Jeanne;
    • Khuri, Fadlo R.;
    • Sun, Shi‐Yong
    Publication type:
    Article
    18
    19
    20
    21